Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $6.5552W HIGH $9.35
Volume
67.84 K
Value Traded
934.73 K
Short % Float
0.51%
-6.44%Week
-5.3%1 Month
+9.2%3 Month
-8.42%6 Month
+29%5 Year
-15.35%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
448.70 M
EPS (TTM)
0.38
P/E Ratio
20.52
Ent. Value
389.97 M
Total Shares
57.71 M
Float Shares
31.66 M
Insiders
45.13%
Institutions
16.45%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
KMDA Catalyst Timeline
Dated clinical, regulatory and corporate events for Kamada Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kamada Ltd.
513Total events
13Upcoming
114Tier-1 (high impact)
2015 to 2030Coverage
Upcoming catalysts 2
Event history 50
▲Product LaunchUstekinumab-KamadaPost-Market
Commercial launch of Ustekinumab-Kamada biosimilar in Israel
chronic immune-mediated inflammatory diseases, including plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitissource ↗
▲Product LaunchEnoxaparin-KamadaPost-Market
Commercial launch of Enoxaparin-Kamada biosimilar in Israel
prevention and treatment of thromboembolic disorders, including deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for use in certain acute coronary syndrome settingssource ↗
▲Timing GuidanceKedRABApprovedPresentation
Kamada confirms sufficient KedRAB supply and manufacturing capacity to meet increased U.S. demand
rabies post-exposure prophylaxissource ↗
●Safety Signal DisclosedSafety
CDC publishes Health Advisory reporting significant year-over-year increase in U.S. rabies exposures and rabies immunoglobulin utilization
human rabies exposures and rabies post-exposure prophylaxis (PEP)source ↗
▲Partnership / LicenseCorporate
Three-year $50 million plasma supply agreement with leading biopharma company
▲FDA ApprovalFDA Decision
FDA approval of new in-house RFFIT laboratory for rabies potency testing
▲Other Regulator MilestoneEx-US Regulatory
Israeli Ministry of Health approval of new RFFIT laboratory
▲FDA ApprovalFDA Decision
FDA approval of Kamada Plasma's collection center in San Antonio, TX
plasma collection centersource ↗
▲Partnership / LicenseCorporate
Extended Canadian Blood Services tender for WINRHO, HEPAGAM, CYTOGAM, VARIZIG for two years
▲Equity OfferingCorporate
Adopted annual cash dividend policy and declared $0.25 per share dividend
●Oral PresentationPresentation
Conference call and live webcast to discuss 2025 financial results
▼Trial DiscontinuedTrial
Termination of Phase 3 InnovAATe clinical trial
Alpha-1 Antitrypsin Deficiencysource ↗
◆Quarterly UpdateCorporate
2025 financial results to be published in first half of March 2026
▲Partnership / LicenseKedRABApprovedCorporate
Kedrion exercises option to extend KEDRAB distribution agreement through March 2026
Rabies post-exposure prophylaxissource ↗
▲FDA ApprovalFDA Decision
FDA approval of Kamada Plasma's collection center in San Antonio, TX
▲Quarterly UpdateCorporate
Affirms 2025 financial guidance of $178-$182 million revenues and $40-$44 million adjusted EBITDA
▲Poster PresentationCYTOGAMFiledPresentation
Three posters presented at ISHLT 2026 on CYTOGAM study results
Cytomegalovirus (CMV) in solid organ transplantationsource ↗
▲Oral PresentationCYTOGAMFiledPresentation
ISHLT 2026 presentation of CYTOGAM study results
cytomegalovirus (CMV) in solid organ transplantationsource ↗
◆Interim AnalysisTrial
Interim futility analysis for InnovAATe trial
Alpha-1 Antitrypsin Deficiencysource ↗
▼Trial DiscontinuedTrial
Discontinued Phase 3 Inhaled AAT clinical trial
Alpha-1 Antitrypsin Deficiencysource ↗
▲Supply DisruptionCMC / Inspection
Canadian Blood Services extends supply tender for WINRHO, HEPAGAM, CYTOGAM, VARIZIG for two years
●Quarterly UpdateCorporate
Reiterated full-year 2025 revenue guidance of $178M-$182M and adjusted EBITDA of $40M-$44M
◆Quarterly UpdateCorporate
Annual General Meeting of Shareholders to vote on director elections, compensation, and other proposals
▼Trial Stopped FutilityTrial
Phase 3 InnovAATe trial of Inhaled AAT discontinued due to futility
Alpha-1 Antitrypsin Deficiency (AATD)source ↗
●Quarterly UpdateCorporate
Reiterated 2025 full-year guidance: revenue $178M-$182M, adjusted EBITDA $40M-$44M
◆Interim AnalysisTrial
Interim futility analysis for InnovAATe trial expected by end of 2025
Alpha-1 Antitrypsin Deficiencysource ↗
▲First Patient DosedCYTOGAMFiledTrial
First patient enrolled in SHIELD trial of CYTOGAM for late CMV prevention in kidney transplant
prevention of late Cytomegalovirus infection in kidney transplant recipientssource ↗
▲Trial InitiationCYTOGAMFiledTrial
Initiation of investigator-initiated SHIELD study for CYTOGAM
Cytomegalovirus (CMV) in solid organ transplantationsource ↗
◆Oral PresentationPresentation
Kamada CEO presentation at H.C. Wainwright 27th Annual Global Investment Conference
◆Oral PresentationPresentation
Kamada CEO presentation at 2025 Wells Fargo Healthcare Conference
▲FDA ApprovalFDA Decision
FDA approval of supplement to BLA for Kamada Plasma's collection center in Houston, TX
Past FDA Catalysts and PDUFA Decisions
How KMDA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2021-01-31 | anti-SARS-CoV-2 plasma-derived hyperimmune immunoglobulin (IgG) product | Phase 1/2 topline data readout | Phase 1/2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D24 / 100
Pipeline Score
$3M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 85%
Micro Cap(rank 559 of 658)
Percentile Rank
Kamada Ltd. faces pipeline headwinds (24/100), with $12M risk-adjusted pipeline value, led by Active rabies vaccine in Rabies (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Active rabies vaccine VaccineCompletedNCT02040090 | Rabies | Phase 2 | COMPLETED | 118 | Aug 1, 2014 |
Clinical Trial Results
Readouts, endpoints and source filings for every KMDA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Plasma-Derived Hyperimmune Globulin (IgG) | COVID-19 | Phase 1/2 | 2021-03-31 | total patients: 12; patients recovered: 11; discharged by day 5: 7; discharged by day 9: 4Read More | Kamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyperimmune Globulin (IgG) Treatment for Coronavirus Disease (COVID-19) As Previously Reported, 11 of the 12 Patients Recovered anRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Brenner YaelOfficer (VP Quality) | Option | 5,000 11,266 held | $5.93 | 09/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KMDA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in KMDA for Q2 2026. | ||||
KMDA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-02-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KMDA ranks across every disease it competes in
Competitive Position is a premium feature
See how KMDA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKMDA News
KMDA▼ -1.5%today
Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel
Kamada Ltd. has expanded its biosimilars portfolio with the launch of two new products in Israel: Ustekinumab-Kamada and Enoxaparin-Kamada. This addition complements its existing biosimilars and is expected to significantly contribute to revenue growth, with projections of $20-$25 million by 2030. The company aims to continue expanding its offerings in the biosimilars market.
Read more →KMDA▲ +5.9%on this news
CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand
Kamada Ltd. has confirmed that it has adequate supply and manufacturing capacity for KedRAB, an anti-rabies immunoglobulin, to meet the rising demand following a CDC report highlighting a significant increase in rabies exposures in the U.S. The company is committed to ensuring a reliable supply of this critical product, which is one of only two FDA-approved options available in the market.
Read more →KMDAKamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Kamada Ltd. announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference, with CEO Amir London scheduled to present on September 15, 2026. The company will also facilitate one-on-one meetings with investors during the event. Kamada is recognized for its specialty plasma-derived therapies and aims to drive growth through various strategic initiatives.
Read more →KMDAKamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
Kamada Ltd. announced a tax ruling from the Israel Tax Authority regarding a cash dividend of $0.17 per share. Shareholders may qualify for a reduced withholding tax rate if they meet specific criteria. The company appointed IBI Trust Management as a processing agent to assist shareholders with the necessary documentation for tax benefits.
Read more →KMDAKamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026
Kamada Ltd. announced a cash dividend of $0.17 per share, totaling approximately $9.8 million, to be paid on September 17, 2026. This decision follows the company's record-high financial results for the first half of 2026, showcasing its solid cash position. CEO Amir London expressed confidence in the company's growth prospects and commitment to shareholder returns.
Read more →KMDAKamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance
Kamada Ltd. reported record-high financial results for the first half and second quarter of 2026, with revenues reaching $100.2 million and adjusted EBITDA of $25.7 million. The company affirmed its annual guidance of $200 million to $205 million in revenues, indicating strong growth prospects. A new three-year sales agreement to supply plasma worth approximately $50 million was also secured, contributing to their optimistic outlook.
Read more →KMDAKamada Announces Planned Transition of Chief Financial Officer
Kamada Ltd. announced the upcoming transition of its Chief Financial Officer, Chaime Orlev, effective December 31, 2026. Orlev, who has served in this role since 2017, will assist in the transition to a new CFO. The CEO praised Orlev's contributions to the company's growth and financial stability.
Read more →KMDAKamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026
Kamada Ltd. will announce its financial results for Q2 and the first half of 2026 on August 12, 2026. The announcement will occur before U.S. markets open, followed by a conference call at 8:30 AM ET for discussion and Q&A. The company continues to focus on growth through product commercialization and plasma collection operations.
Read more →KMDAKamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies
Kamada Ltd. has announced a three-year agreement to supply plasma to a leading biopharmaceutical company, projected to generate approximately $50 million in revenue. The agreement highlights Kamada's investment in its plasma collection centers in Texas, which are expected to support significant production capacity. Initial sales are anticipated to begin in the fourth quarter of 2026.
Read more →KMDAKamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting
Kamada Ltd. showcased results from an Investigator-Initiated Study on CYTOGAM at the 2026 ISHLT annual meeting. The study indicated that CMV high-risk lung transplant recipients receiving CMVIG prophylaxis had better clinical outcomes than those who did not. These findings may shift the understanding of CMV management in lung transplantation, emphasizing the potential immune modulation benefits of CYTOGAM.
Read more →KMDAKAMADA LTD. 2 Holzman Street Weizmann Science Park P.O. Box 4081 Rehovot 7670402, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Dear Shareholder: We cordially invite you to attend the Annual General Meeting of
Kamada Ltd. will hold its Annual General Meeting of Shareholders at its office in Rehovot, Israel, on August 5, 2026. Shareholders are invited to consider the re-election of directors, approval of options for director nominees, and to review financial statements for the year ended December 31, 2025. The Board recommends a vote in favor of all proposals, encouraging full participation from shareholders. The meeting's outcomes will directly influence the company’s governance and future direction.
Read more →KMDAKamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory
Kamada Ltd. has received FDA approval for its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory, enhancing its capabilities in rabies-neutralizing antibody testing. This facility, located in Beit Kama, Israel, will improve the quality control processes for its products KEDRAB and KAMRAB. The lab is designed to meet high safety and quality standards, reflecting Kamada's commitment to scientific excellence.
Read more →KMDA▼ -6.8%on this news
Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year
Kamada Ltd. reported a revenue increase of 3% year-over-year for Q1-2026, totaling $45.2 million, with an adjusted EBITDA margin of 26%. The company reaffirmed its annual guidance of $200-$205 million in revenues and $50-$53 million in adjusted EBITDA, citing increased underlying demand for its products. A temporary shipment delay affected Q1 results, but overall growth expectations remain strong.
Read more →KMDAKamada to Announce First Quarter 2026 Financial Results on May 13, 2026
Kamada Ltd. announced its upcoming financial results for the first quarter of 2026, set to be released on May 13, 2026, prior to U.S. market opening. The company will host a conference call at 8:30 AM ET on the same day to discuss these results with the investment community. Kamada, known for its specialty plasma-derived therapies, is focusing on growth through its product portfolio, plasma collection operations, and potential mergers and acquisitions.
Read more →KMDAKamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas
Kamada Ltd. has received FDA approval for its plasma collection center in San Antonio, Texas. The facility is designed to collect both normal and specialty plasma, with an annual capacity of approximately 50,000 liters. It is expected to generate significant revenue and become one of the largest centers for specialty plasma in the U.S. Kamada plans to seek EMA approval for the site as well.
Read more →KMDAKamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth
Kamada Ltd. reported impressive financial results for 2025, achieving record revenues and EBITDA, reflecting a robust growth trajectory. The company maintains a positive outlook for 2026, reiterating revenue and EBITDA guidance that indicates continued expansion. A new annual cash dividend policy was introduced, further demonstrating Kamada's strong financial position. However, the company faced challenges with a decline in gross margin and a decrease in operating cash flow compared to the previous year.
Read more →KMDAKamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy
Kamada Ltd. has declared a cash dividend of $0.25 per share, to be distributed on April 6, 2026, in line with its newly adopted annual cash dividend policy. The company reported record revenue and profitability for the full year 2025, which contributes to their strong financial position. This dividend is part of Kamada's strategy to reinforce shareholder confidence and facilitate future investments and growth initiatives.
Read more →KMDAKamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026
Kamada Ltd. will release its financial results for Q4 and fiscal year 2025 on March 11, 2026. The announcement includes a conference call for investors to discuss the results. Kamada is recognized for its specialty plasma-derived products and aims for profitable growth through various strategic initiatives.
Read more →KMDA▲ +5.8%on this news
Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance
Kamada Ltd. has announced its financial guidance for 2026, projecting revenues of $200-$205 million and adjusted EBITDA of $50-$53 million, reflecting double-digit growth. The forecast is based on the continued organic growth of its diverse product portfolio across multiple markets. The company also reaffirmed its 2025 guidance, indicating strong operational performance and cash flow. However, it faces potential challenges from reduced royalty payments and geopolitical risks.
Read more →About Kamada Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next KMDA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime